RVMD

Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit

Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting

Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors

Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021

Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress

Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences

Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock